Insmed Incorporated (NASDAQ:INSM) Insider Sells $392,786.08 in Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 6,172 shares of the business’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $63.64, for a total transaction of $392,786.08. Following the transaction, the insider now owns 101,549 shares in the company, valued at approximately $6,462,578.36. The trade was a 5.73 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Martina M.D. Flammer also recently made the following trade(s):

• On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The shares were sold at an average price of $65.91, for a total value of $220,403.04.

Insmed Stock Down 0.7 %

Shares of NASDAQ:INSM opened at $65.25 on Monday. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a market cap of $11.67 billion, a P/E ratio of -11.76 and a beta of 1.12. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The company’s 50-day moving average price is $71.23 and its two-hundred day moving average price is $72.46.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.36 million. During the same period in the prior year, the company posted ($1.10) earnings per share. Insmed’s quarterly revenue was up 18.1% compared to the same quarter last year. As a group, research analysts forecast that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

INSM has been the topic of several recent research reports. Bank of America lifted their price objective on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. JPMorgan Chase & Co. boosted their price target on shares of Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a report on Friday, November 22nd. Truist Financial reiterated a “buy” rating and set a $105.00 target price (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $90.00 price target on shares of Insmed in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and an average price target of $83.67.

Hedge Funds Weigh In On Insmed

Large investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in Insmed by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 3,813,384 shares of the biopharmaceutical company’s stock valued at $278,432,000 after purchasing an additional 172,664 shares during the period. Darwin Global Management Ltd. acquired a new position in Insmed in the second quarter valued at approximately $237,076,000. Principal Financial Group Inc. boosted its stake in Insmed by 12.9% in the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock valued at $136,648,000 after acquiring an additional 214,130 shares during the last quarter. Clearbridge Investments LLC grew its holdings in Insmed by 76.8% during the 2nd quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company’s stock worth $110,212,000 after acquiring an additional 714,539 shares during the period. Finally, Vestal Point Capital LP raised its position in shares of Insmed by 113.3% during the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after acquiring an additional 850,000 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.